Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

Core Viewpoint - Teva Pharmaceutical Industries Ltd. has initiated IND-enabling studies for BD9, a dual-specific multibody targeting TSLP and IL-13, aimed at treating TH2-driven inflammatory diseases such as atopic dermatitis and asthma [1][2][7] Group 1: Teva's Commitment and Innovation - Teva's development of BD9 highlights its commitment to addressing unmet medical needs through advanced scientific approaches [2] - The initiation of IND-enabling studies is a significant milestone that could lead to clinical trials, providing new therapeutic options for underserved patient populations [2][3] - Teva aims to enhance health outcomes and access through innovative therapies, reflecting its focus on transformative medicine [2][3] Group 2: Collaboration with Biolojic Design - Teva has an exclusive license to develop BD9 globally, with Biolojic Design eligible for milestone payments based on various achievements in the development process [3] - Biolojic's next-generation antibody platform has produced multiple antibodies nearing clinical application, showcasing the advantages of precision antibodies over traditional ones [3][4] - The partnership aligns with Teva's Pivot to Growth strategy, emphasizing innovation in its product pipeline [7] Group 3: Biolojic Design Overview - Biolojic Design specializes in precision antibodies, including multibodies that can bind to multiple targets, addressing complex disease biology [4] - The company utilizes computational biology and AI to design its multibodies, with a focus on autoimmune diseases and oncology [4] - Biolojic has established partnerships with leading biopharmaceutical companies to enhance its capabilities in bringing new medicines to market [4] Group 4: Teva's Operational Background - Teva has over 120 years of experience in the biopharmaceutical industry, with a workforce of 37,000 employees across 57 markets [5] - The company is dedicated to developing both innovative medicines and generics, aiming to meet current and future patient needs [5]